SPIMACO signs agreement with CanSinoBIO to supply vaccines

26/03/2025 Argaam
Logo ofSaudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO)

Logo of Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO)

Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) signed a collaboration agreement with CanSinoBIO to supply, produce, and commercialize MCV4 vaccines in Saudi Arabia and selected MENA markets.

 

 

In a statement to Tadawul, the company said the expected revenues from this agreement in the fifth year after launch represent about 4% of the company’s annual topline for 2023.

 

The five-year contract was signed on March 25. There are no related parties to the contract, SPIMACO added.

 

According to Argaam data, SPIMACO’s revenues stood at SAR 1.65 billion in 2023, implying that 4% of the total topline amounts to SAR 66.12 million.

Comments {{getCommentCount()}}

Be the first to comment

{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
{{comment.Replies.length}}
تعديل
loader Train
Report
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.